BioInvest News Novavax (NVAX) – This morning, NVAX reported disappointing top-line data from the ResVax Phase III PREPARE study for infant RSV prevention. Unfortunately, the trial failed on the primary endpoint of reducing medically significant RSV lower respiratory tract infection (LRTI).
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.